Maxim Group Believes BeiGene Ltd (NASDAQ: BGNE) Won’t Stop Here

By Ryan Adsit

Maxim Group analyst Gabrielle Zhou reiterated a Buy rating on BeiGene Ltd (NASDAQ: BGNE) today and set a price target of $52. The company’s shares opened today at $41.13, close to its 52-week high of $42.28.

Zhou noted:

“BeiGene announced positive preliminary Phase I data for BGB-A317 (anti- PD-1) in combination with BGB-290 (PARP inhibitor) in solid tumors at ASCO (American Society for Clinical Oncology).”

According to TipRanks.com, Zhou is ranked 0 out of 5 stars with an average return of -14.1% and a 25.5% success rate. Zhou covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, ContraVir Pharmaceuticals Inc, and Sciclone Pharmaceuticals.

BeiGene Ltd has an analyst consensus of Moderate Buy, with a price target consensus of $52.

The company has a one year high of $42.28 and a one year low of $24.53. Currently, BeiGene Ltd has an average volume of 94.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BeiGene Ltd. operates as a holding company, which engages in the research and development of biopharmaceutical products. It develops immuno-oncology drugs for cancer treatment. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.